Loading...
OTCM
VIVXF
Market cap0USD
Dec 12, Last price  
0.00USD
Name

Avivagen Inc

Chart & performance

D1W1MN
OTCM:VIVXF chart
P/E
0.00
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
39.52%
Revenues
939k
-27.53%
54,711359,051412,2491,183,516184,536289,314417,564110,517295,671163,966161,190255,6601,072,572977,4511,177,8571,295,991939,173
Net income
-6m
L-5.13%
-812,516-1,038,067-1,268,955-1,344,601-2,779,147-3,509,866-1,973,763-2,024,024-2,080,388-2,003,955-2,752,498-5,135,661-4,834,059-4,836,420-4,751,287-6,394,159-6,066,206
CFO
-3m
L-32.24%
-687,411-950,279-639,492-1,138,795-1,931,235-1,829,233-2,058,309-2,653,067-1,768,258-1,641,835-2,184,549-4,772,743-3,809,397-3,522,092-3,335,688-4,599,045-3,116,538

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Avivagen Inc. is a life sciences enterprise that invents and sells specialized products, primarily for animal feed, aimed at bolstering the immune systems of livestock. These solutions are designed to enhance animals' health, leading to improved growth and overall productivity. The company's diverse product lineup features OxC-beta Livestock, a crucial premix for farm animal diets. Beyond agriculture, Avivagen also manufactures health supplements such as Vivamune and Dr. Tobias-branded chews for dogs, along with the Dr. Tobias Beta blend, formulated to support human immunity. Established in 2005 and based in Ottawa, Canada, Avivagen Inc. distributes its offerings across numerous international markets, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia.

Key people

G.F. Kym Anthony
Chief Executive Officer, Vice Chairman of the Board · since 2023
Ira Levy
Interim Chief Financial Officer · since 2022
James Nickerson
Executive Vice President - Business Development and Product Innovation · since 2023
Graham Burton
Chief Scientific Officer, Director · since 2017
David Hankinson
Independent Chairman of the Board · since 2023
Paul Mesburis
Independent Director · since 2019
IPO date
Mar 04, 2004
Employees
13
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT